Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2023-09-18 Director's Dealing
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 99% confidence The document is a structured template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a 'Purchase of shares' transaction involving an executive's closely associated person (Øystein Stray Spetalen) in Vistin Pharma ASA. This content directly corresponds to the reporting requirements for insider trading or director/executive share transactions. Based on the provided definitions, this aligns perfectly with 'Director's Dealing' (Code: DIRS). The document is not a general regulatory filing (RNS) because it fits a specific category, nor is it a report announcement (RPA) as it contains the actual transaction details.
2023-09-18 English
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document text explicitly states 'Mandatory notification of trade' and details a purchase of shares by an entity closely associated with a board member (Saga Pure ASA and Øystein Stray Spetalen). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2023-09-18 English
Mandatory notification of trade in Vistin Pharma ASA
Director's Dealing Classification · 100% confidence The document is a structured notification template titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details a specific transaction: the purchase of 200,000 shares of Vistin Pharma ASA by an entity closely associated with a board member. This content directly corresponds to the definition of Director's Dealing (insider trades by executives/directors or associated persons). Therefore, the appropriate filing code is DIRS.
2023-08-26 English
Mandatory notification of trade in Vistin Pharma ASA
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Mandatory notification of trade' involving a purchase of shares by an entity closely associated with a board member (Ferncliff Listed DAI AS associated with Øystein Stray Spetalen). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2023-08-26 English
Vistin Pharma ASA: Second quarter and first half 2023 financial results
Investor Presentation Classification · 100% confidence The document is a presentation titled 'Agenda' with sections for 'Highlights', 'Operational review', 'Financial review', and 'Appendix'. It contains detailed financial tables (Income Statement, Balance Sheet) for Q2 2023 and YTD 2023, alongside strategic business updates, market analysis, and shareholder information. This structure and content are characteristic of an investor presentation used to communicate quarterly performance and outlook to stakeholders. Q2 2023
2023-08-23 English
Vistin Pharma ASA: Second quarter and first half 2023 financial results
Interim / Quarterly Report Classification · 100% confidence The document is titled 'VISTIN PHARMA ASA – SECOND QUARTER AND FIRST HALF REPORT 2023'. It contains detailed financial statements, including revenue, EBITDA, cash flow, balance sheet, and operational analysis for the specified interim period. It is not an announcement of a report, but the report itself, and it includes substantive financial data, thus fitting the definition of an Interim/Quarterly Report. H1 2023
2023-08-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.